4.3 Article

Muscle dysfunction in axial spondylarthritis: the MyoSpA study

期刊

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
卷 40, 期 2, 页码 267-273

出版社

CLINICAL & EXPER RHEUMATOLOGY

关键词

spondylarthritis; sarcopenia; body composition; muscle strength; physical performance

资金

  1. iNOVA4Health
  2. Novartis Portugal
  3. Portuguese Society of Rheumatology

向作者/读者索取更多资源

This study aimed to compare muscle physical properties, strength, mass, physical performance, and the prevalence of sarcopenia between patients with axial spondylarthritis (axSpA) and healthy controls (HC). The results showed that there was no significant difference in muscle physical properties between axSpA patients and HC, despite slightly higher lumbar stiffness. There was also no sarcopenia observed in either group. However, axSpA patients had lower strength and physical performance compared to HC, suggesting possible muscle dysfunction.
Objective We aimed to investigate muscle physical properties, strength, mass, physical performance, and the prevalence of sarcopenia in patients with axial spondylarthritis (axSpA) compared to the healthy controls (HC). Methods We performed a cross-sectional study on 54 participants: 27 patients with axSpA and 27 HC, matched by age, gender, and level of physical activity. Muscle physical properties (stiffness, tone and elasticity), muscle strength (five-times sit-to-stand [5STS] test), muscle mass, physical performance (measured through gait speed) and sarcopenia were compared between the groups. Linear regression models were conducted allowing adjustment for relevant variables. Results Patients with axSpA (mean age 36.5 (SD 7.5) years, 67% males, mean disease duration 6.5 (3.2) years) had no significant difference in segmental muscle stiffness, tone or elasticity, compared with the HC, despite showing a slight numerically higher lower lumbar (L3-L4) stiffness [median 246.5 (IQR 230.5-286.5) vs. 232.5 (211.0-293.5), p=0.38]. No participants presented sarcopenia. Patients with axSpA, compared to the HC, had lower total strength [B=1.88 (95% CI 0.43;3.33)], as well as lower strength in the upper (B=-17.02 (-27.33;-6.70)] and lower limbs [B= -11.14 (-18.25;-4.04)], independently of muscle physical properties. Patients had also significantly lower gait speed than the HC [B= -0.11 (-0.21;-0.01)], adjusted for muscle mass, strength and muscle physical properties. Conclusion Young axSpA patients with a relatively short disease duration presented similar segmental muscle physical properties as the HC and had no sarcopenia. Patients with axSpA had reduced physical performance and lower strength compared to the HC, despite normal muscle mass, suggesting a possible muscle dysfunction. Gait characteristics may be a potential biomarker of interest in axSpA.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据